Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Laboratory Corporation of America Holdings (“Labcorp” or “the Company”) (NYSE: LH). Investors who purchased Labcorp securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/lh.

The investigation concerns whether Labcorp and certain of its officers and/or directors have violated federal securities laws.

On January 1, 2022, The New York Times published an article regarding Labcorp and questioned the accuracy of its noninvasive prenatal tests. The article stated Labcorp’s tests are incorrect up to 85% of the time and that false positives result in follow-up testing which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy." Following this news, Labcorp stock dropped 5% on January 3, 2022.

If you are aware of any facts relating to this investigation or purchased Labcorp shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/lh. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127006007/en/